Source: BEFREE ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs113488022
rs113488022
BRAF
0.040 GeneticVariation BEFREE Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. 31058533

2019
dbSNP: rs121913377
rs121913377
BRAF
0.040 GeneticVariation BEFREE Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients. 31058533

2019
dbSNP: rs113488022
rs113488022
BRAF
0.040 GeneticVariation BEFREE This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. 28475671

2017
dbSNP: rs121913377
rs121913377
BRAF
0.040 GeneticVariation BEFREE This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. 28475671

2017
dbSNP: rs113488022
rs113488022
BRAF
0.040 GeneticVariation BEFREE Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases. 25746037

2015
dbSNP: rs121913377
rs121913377
BRAF
0.040 GeneticVariation BEFREE Researchers retrospectively reviewed medical records of all patients at our institution with surgically incurable BRAF V600E mutated stage III or limited stage IV melanoma treated with induction vemurafenib, stopped electively during ongoing response, followed by consolidative radiation therapy with or without intervening surgery to debulk nodal metastases. 25746037

2015
dbSNP: rs113488022
rs113488022
BRAF
0.040 GeneticVariation BEFREE In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo. 25265492

2014
dbSNP: rs121913377
rs121913377
BRAF
0.040 GeneticVariation BEFREE In this phase 3 trial, we randomly assigned 423 previously untreated patients who had unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation to receive a combination of dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily) or dabrafenib and placebo. 25265492

2014
dbSNP: rs121913227
rs121913227
BRAF
0.010 GeneticVariation BEFREE We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma. 26037941

2015
dbSNP: rs121913255
rs121913255
NRAS
0.010 GeneticVariation BEFREE Subsequently, we quantified ctDNA ((V600E)BRAF,(V600K)BRAF or (Q61H)NRAS) in 6 stage IV melanoma patients across several time points during their treatment course. 26095797

2015
dbSNP: rs121913254
rs121913254
NRAS
0.010 GeneticVariation BEFREE Carcinogen treatment in mouse selectively expressing activated N-Ras Q61K in melanocytes recapitulates metastatic cutaneous melanoma development. 22128787

2012